CTOs on the Move

Synergy Pharmaceuticals

www.synergypharma.com

 
Synergy is a gastrointestinal-focused biopharmaceutical company committed to science-based innovation, providing novel treatment options for patients and healthcare providers, rewarding opportunities for our employees, and creating exceptional value for our shareholders.
  • Number of Employees: 0-25
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Funding

Synergy Pharmaceuticals raised $300M on 09/05/2017

Similar Companies

Regulatory Professionals Inc

Regulatory Professionals Inc is a Milpitas, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

GHOST

Ghost Lifestyle is a premium lifestyle brand of dietary supplements and sports nutrition products that encourages people to rethink the boundaries and lifestyles championed by traditional sports nutrition brands in exchange for an all-encompassing, fit...

Auris Health

Auris is a robotic medical company led by Fred Moll, a pioneer in surgical robotics. Our technology represents the next era of medical innovation: flexible robotics that allow for the least invasive approach entry into the body through its natural open...

Kaup Pharmacy

Kaup Pharmacy is a Fort Recovery, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

PACT Pharma

PACT Pharma is an independent, privately funded company recently launched by Arcus and scientific founders Jim Heath (Caltech), Toni Ribas (UCLA) and David Baltimore (Caltech). PACT`s vision is to be the leader in creating, developing and commercializing cell-based therapies for the cure of cancer. Our mission is to leverage technology developed in the laboratories of Jim Heath and David Baltimore to advance the feasibility, affordability and clinical utilization of personalized neoantigen-specific adoptive cell therapy for cancer. PACT is developing personalized adoptive T cell therapies for the eradication of solid tumors. The identification of neo-epitopes that serve as private mutations for each patient`s cancer creates a unique opportunity to engineer autologous T cells that target and kill tumors expressing these neo-antigens. PACT utilizes technology to identify T cells that recognize the neo-epitope. The unique T-cell receptor (TCR) sequences obtained from these neo-epitope-reactive cells are then engineered into T cells from the patient`s own blood to produce PACT`s therapeutic product: a tsunami of fresh, active T cells that, following infusion into the patient, recognize and attack each patient`s cancer cells.